Cosmos Health Extends and Updates its Agreement to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp – Yahoo Finance

Tapping Into the Fast Growing Multi Billion Dollar U.S. Telehealth Market
CHICAGO, IL / ACCESSWIRE / January 20, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has extended and updated its previously issued non-binding letter of intent to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). Cosmos Health has successfully renegotiated the acquisition price of ZipDoctor to achieve much improved payment terms. The updated letter of intent will remain effective until February 15, 2023.
ZipDoctor Inc., a wholly owned subsidiary of American International Holdings Corp. (OTC: AMIH), is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. ZipDoctor's online telemedicine platform will be available to customers across the United States and offers English and Spanish coverage with virtual visits taking place either via the phone or through a secured video chat platform. ZipDoctor customers will be able to subscribe through their website at and are only required to pay a monthly fee, which is determined based on whether they are an individual, a couple, or a family.
Greg Siokas, Chief Executive Officer of Cosmos Health stated: "We are enthusiastic about the proposed addition of ZipDoctor to Cosmos Heath's family of companies. The telehealth industry is set for strong growth, and we believe that ZipDoctor, with the proper investment from Cosmos, can become a significant player in the space. Furthermore, we intend to expand on ZipDoctor's current primary care and mental health service offerings to include the ability to speak to a doctor to seek additional medical treatments related to and including men's and women's health and wellness issues, weight loss and other similar treatments. Furthermore, we are satisfied with the renegotiated price of the acquisition, as we are always looking to increase our returns on investment."
According to Nova One Advisor, the U.S. Telehealth market size was valued at $23.8 billion in 2021 and is expected to grow to $309.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 45.1% from 2022 to 2030. The shortage of healthcare specialists and primary care physicians in the U.S. is one of the major factors expected to accelerate the market growth in the U.S. according to the Association of American Medical Colleges (AAMC) estimation, there is an estimated shortage of both primary and specialty care physicians between 37,800 and 124,000 physicians by 2034. In 2021, the Centers for Medicare and Medicaid Services expanded reimbursable telehealth codes for the 2021 physician fee schedule.
Update on the ongoing review of COSM trading patterns: Cosmos would like to inform investors that it has recently received trading activity data from Shareholder Intelligence Services, LLC. Management is carefully reviewing the data in order to develop its next course of action.
About Cosmos Health, Inc
Cosmos Health Inc. (Nasdaq:COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at and
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Lytham Partners, LLC
Ben Shamsian
P: 646-829-9701
SOURCE: Cosmos Health Inc.

View source version on

Related Quotes
Profit from folly. Don’t participate in it.
Let's talk about a hot stock in the tech industry that's flying under the radar. There may be pizza and a movie at the end.
The only single-ticker investment that this Fool would trust with his entire life savings might surprise you.
In this article, we will take a look at the 10 dirt cheap stocks to buy. To see more such companies, go directly to 5 Dirt Cheap Stocks To Buy. Amid a disastrous 2022 some analysts and market pundits are predicting a market rebound in late 2023 or 2024. Historically, market declines have given a […]
With the market selling off over the past year, many stocks are cheaper than they were. However, some stand out because they're ridiculously cheap compared to their peers. Right now, two stocks with absurdly low valuations are Energy Transfer (NYSE: ET) and Medical Properties Trust (NYSE: MPW).
Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett has made millions for his early investors. A $1,000 investment in Berkshire stock in 1965, when Buffett took control of the company, would have grown to more than $36 million in 2021 if the investor remained invested. Among Berkshire's largest holdings, there are a few that stand out for their durable brands and competitive strengths.
Dow Jones futures: Tech stocks are reviving, leading Friday's market rally. Tesla and Boeing headline market-moving earnings reports on tap.
Kinder Morgan (NYSE: KMI) formed a new business unit in 2021 to capitalize on commercial opportunities as the global economy transitions to lower-carbon energy. The initial focus of its new Energy Transition Ventures group has been building a renewable natural gas platform. It has also been evaluating opportunities in other sectors, including carbon capture, utilization, and sequestration (CCUS).
DNB Asset Management increased positions in Tesla and Plug Power, while slashing its stake in General Motors in the fourth quarter.
Why settle for average returns when you can earn more with growth stocks? These companies consistently exceed industry averages in revenue and earnings, making them a smart choice for your investment portfolio in 2023.
If you want $10,000 in passive income in 2023, it's possible to do so by investing a total of $110,000 in these high-yield dividend stocks. As a BDC, Ares provides financing to small to medium-sized businesses. The company must return at least 90% of its taxable income to shareholders in the form of dividends.
These best-of-breed names belong to a select group of 48 companies that have raised their dividends for at least 50 consecutive years.
Tough times are coming — but that doesn't mean you can't make money.
(Bloomberg) — The pause in the stock market’s strong start to 2023 underscores the main question vexing much of Wall Street: When will it be safe to start buying again? Most Read from BloombergPrince Andrew and Virginia Giuffre Photo Is Fake: Ghislaine MaxwellHolmes Belongs in Prison, Not $13,000-a-Month Manor, US SaysInvestors Aren't Sure When to Dive Back Into US Stock MarketChina Says Covid Deaths Top 12,600 and More Than 1 Billion InfectedTen People Killed in Mass Shooting Near Los AngelesY
‘Both are insistent that I'm taking money that is morally theirs. There's no changing their mind.’
The government is in a doom spiral of spending and borrowing
Nvidia is a giant in data centers and gaming, but semiconductor companies are bracing for a bumpy 2023. Is Nvidia stock a buy right now? Recently, World Semiconductor Trade Statistics predicted that chip sales will decline 4.1% in 2023.
The boom in special purpose acquisition companies (SPACs) and flurry of initial public offerings (IPOs) in 2020 and 2021 produced a lot of public companies that are starting to run into serious financial trouble in this difficult economic environment. Banking disruptor SoFi Technologies (NASDAQ: SOFI) was a product of the SPAC boom, and like many of its fellow ex-SPACs, its stock has performed poorly — down about 79% from the peak. In addition to the general cooling off of high-growth stocks, investors are frustrated that SoFi's core student loan refinancing business remains at a virtual standstill, and there are worries that higher interest rates could hurt its lending operations, by far the more profitable side of the business.
These supercharged income stocks, with an average yield of 10.06%, can generate $1,000 in annual income with an initial investment of less than $10,000.
At the World Economic Forum in Davos, the world’s business leaders fretted over the possibility that inflation won’t fall back to central banks’ targets.



Learn More →

Leave a Reply

Your email address will not be published. Required fields are marked *